51 completed, 8 terminated, 7 unknown, 1 enrolling by invitation. 16 Phase 2, 14 Phase 4, 10 Phase 3, 9 Phase 1, 8 Not applicable.
Follow Herpes Genitalis: new trials by email Literature Review of Herpes Genitalis trials Research Report on Herpes Genitalis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination Low-Dose Cohort, Mid-Dose Cohort, High-Dose Cohort - Genital Herpes | Phase 1 | Enrolling by invitation | Changchun BCHT Biotechnology Co. | 144 | 2025-10-13 | 2026-01-09 |
| A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes ABI-1179, ABI-1179 Placebo - Recurrent Genital Herpes Simplex Type 2 | Phase 1 | Completed | Assembly Biosciences | 103 | 2024-12-08 | 2026-03-23 |
| A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes ABI-5366, ABI-5366 Placebo - Recurrent Genital Herpes Simplex Type 2 | Phase 1 | Completed | Assembly Biosciences | 115 | 2024-05-30 | 2026-03-30 |
| Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes Placebo, UB-621 low-dose, UB-621 high-dose - Recurrent Genital Herpes | Phase 2 | Not yet recruiting | UBP Greater China (Shanghai) Co., Ltd | 200 | 2023-12-01 | 2022-10-03 |
| UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals UB-621 - Recurrent Genital Herpes | Phase 2 | Unknown | UBP Greater China (Shanghai) Co., Ltd | 44 | 2023-10-01 | 2022-05-18 |
| A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes mRNA-1608, BEXSERO - Genital Herpes | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 303 | 2023-09-06 | 2026-05-08 |
| A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 UB-621, Placebo - Genital Herpes | Phase 2 | Unknown | United BioPharma | 80 | 2023-06-01 | 2022-10-03 |
| NOWDx Test for the Diagnosis of Herpes Simplex Virus Type 2 Diagnostic Test: NOWDx HSV-2 Test - HSV-2 Infection, Herpes Simplex Virus Infection | Withdrawn | NOWDiagnostics, Inc. | 2023-03-01 | 2024-02-29 | ||
| Treating Genital Herpes Infection to Reduce Racial Disparities in the Risk of Severe Maternal Morbidity Genital Herpes Simplex, Maternal Morbidity | Unknown | Kaiser Permanente | 339000 | 2023-01-08 | 2024-04-24 | |
| Knowledge of Young Adults About Genital Herpes data collection - Genital Herpes | Unknown | Université de Reims Champagne-Ardenne | 2000 | 2022-12-02 | 2023-01-09 | |
| A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease Genital Herpes, Patient Engagement | Completed | Rational Vaccines Inc | 68 | 2022-08-03 | 2023-01-18 | |
| A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3 - Herpes Simplex | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 505 | 2022-03-07 | 2025-09-08 |
| An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe. Blood sampling, Anogenital lesion swab collection - Herpes Genitalis | Completed | GlaxoSmithKline | 537 | 2021-06-09 | 2025-03-07 | |
| Study of 2LHERP® in Genital Herpes Infections 2LHERP®, Placebo - Herpes Simplex, Genital | Phase 4 | Terminated | Labo'Life | 6 | 2021-01-25 | 2023-10-10 |
| Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2 HSV 2 Formulation 1, HSV 2 Formulation 2, HSV 2 Formulation 3 - Genital Herpes | Phase 1 | Terminated | Sanofi Pasteur, a Sanofi Company | 24 | 2020-02-18 | 2022-10-25 |
| Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection HDIT101, Valaciclovir, HDIT101 placebo - Herpes Genitalis | Phase 2 | Completed | Heidelberg ImmunoTherapeutics GmbH | 122 | 2019-11-15 | 2022-01-18 |
| Safety and Efficacy of Laser Therapy in Gynaecology Herpes Genitalis, Genital Wart | Unknown | Juna d.o.o. | 300 | 2019-07-24 | 2019-08-30 | |
| Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel Kagocel+Valacyclovir, Valacyclovir - Herpes, Herpes Simplex | Completed | Nearmedic Plus LLC | 45 | 2017-10-30 | 2020-12-11 | |
| Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection GEN-003, Matrix-M2, 0.9% normal saline - Genital Herpes, HSV-2 Infection | Phase 2 | Terminated | Genocea Biosciences, Inc. | 33 | 2017-05-24 | 2019-02-19 |
| The VIBLOK SAfety and perFormancE Trial VIBLOK barrier cream - HSV-2 Infection, Genital Herpes | Not applicable | Completed | CLJI Worldwide | 82 | 2017-03-27 | 2020-02-13 |
Showing 20 of 69. Sign in to see all of them.
Herpes Simplex (17) · HIV Infections (15) · Acquired Immunodeficiency Syndrome (4) · Sexually Transmitted Diseases (4) · Anus Diseases (3) · Herpes Zoster (3) · Recurrence (3) · AIDS-Related Complex (2) · Chlamydia Infections (2) · Gonorrhea (2) · Sexual Behavior (2) · Syphilis (2) · Coitus (1) · Condylomata Acuminata (1)
Communicable Diseases (69) · DNA Virus Infections (69) · Female Urogenital Diseases (69) · Female Urogenital Diseases and Pregnancy Complications (69) · Genital Diseases (69) · Genital Diseases, Female (69) · Genital Diseases, Male (69) · Infections (69) · Male Urogenital Diseases (69) · Sexually Transmitted Diseases, Viral (69) · Urogenital Diseases (69) · Virus Diseases (69) · Herpesviridae Infections (68) · Sexually Transmitted Diseases (65) · Herpes Simplex (52)
Valacyclovir (21) · Acyclovir (13) · Famciclovir (6) · ASP2151 (2) · Adjuvants, Pharmaceutic (2) · Circumcision, Male (2) · M2 protein, Influenza A virus (2) · Saline Solution (2) · 4CMenB vaccine (1) · Blood Specimen Collection (1) · Cohort Studies (1) · Data Collection (1) · Melatonin (1) · Sodium Chloride (1) · Watchful Waiting (1)
University of Washington (8) · GlaxoSmithKline (7) · Glaxo Wellcome (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Novartis (4) · French National Agency for Research on AIDS and Viral Hepatitis (3) · Genocea Biosciences, Inc. (3) · Agenus Inc. (2) · Assembly Biosciences (2) · Roxane Laboratories (2) · UBP Greater China (Shanghai) Co., Ltd (2) · AiCuris Anti-infective Cures AG (1) · Astellas Pharma Europe Ltd. (1) · Astellas Pharma Inc (1) · CLJI Worldwide (1)
United States (39) · Australia (6) · South Africa (6) · Canada (5) · Brazil (4) · Uganda (4) · United Kingdom (4) · France (3) · Germany (3) · Zambia (3) · Argentina (2) · Belgium (2) · New Zealand (2) · Spain (2) · Tanzania (2)
Anna Wald, MD, MPH (6) · Connie Celum, MD, MPH (3) · Alan Copa, PharmD (2) · Christine Johnston, MD, MPH (2) · Philippe Mayaud (2) · Adrian Puren (1) · Bertran Auvert, MD (1) · Beth Cobb (1) · Christine Johnston, MD (1) · Connie Celum (1) · Dalu Mohammed, Dr (1)
PMID 22225814, PMID 16044019, PMID 16231970, PMID 17314338, PMID 18532873, PMID 18572080, PMID 18593294, PMID 18596069, PMID 18621575, PMID 19074928, PMID 19086814, PMID 19192993, PMID 19220138, PMID 19220143, PMID 19321868, PMID 19389002, PMID 19404392, PMID 19530940, PMID 19571722, PMID 19616720, PMID 19838129, PMID 19936044, PMID 20011596, PMID 20042848, PMID 20070143, PMID 20089951, PMID 20153888, PMID 20214474, PMID 20370481, PMID 20702659, PMID 21099672, PMID 21104007, PMID 21150554, PMID 21216000, PMID 21399681, PMID 21406077, PMID 21489882, PMID 22183840, PMID 22433279, PMID 22745608, PMID 23061422, PMID 23130818, PMID 25904747, PMID 27997653, PMID 29108000, PMID 29134426, PMID 31058977, PMID 31103365, PMID 33054742, PMID 33362883
2005 (1), K23AI071257 (1), P01AI030731 (1), R01AI050132 (1), R01AI052054 (1), U01AI047981 (1), U01AI052054 (1), U19AI031448 (1)